Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.720
+0.080 (4.88%)
Mar 6, 2026, 1:01 PM EST - Market open
Lexicon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Lexicon Pharmaceuticals stock have an average target of 4.63, with a low estimate of 1.90 and a high estimate of 6.00. The average target predicts an increase of 169.19% from the current stock price of 1.72.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $6 | Strong Buy | Maintains | $4 → $6 | +248.84% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +132.56% | Sep 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $1.2 → $1.9 | Strong Buy | Maintains | $1.2 → $1.9 | +10.47% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +132.56% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +132.56% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
21.38M
from 49.80M
Decreased by -57.07%
Revenue Next Year
26.12M
from 21.38M
Increased by 22.16%
EPS This Year
-0.25
from -0.14
EPS Next Year
-0.23
from -0.25
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 37.8M | 62.5M | |||
| Avg | 21.4M | 26.1M | |||
| Low | n/a | 6.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -24.1% | 192.2% | |||
| Avg | -57.1% | 22.2% | |||
| Low | - | -71.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.18 | -0.12 | |||
| Avg | -0.25 | -0.23 | |||
| Low | -0.31 | -0.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.